Foulks C J, Mills G M, Wright L F
Nephrology Service, Brooke Army Medical Center, San Antonio, Texas.
Postgrad Med J. 1989 Mar;65(761):136-9. doi: 10.1136/pgmj.65.761.136.
Parathyroid hormone (PTH) has been shown in vitro to enhance erythrocyte osmotic fragility (EOF) and has been incriminated as a factor in the anaemia seen in patients with primary hyperparathyroidism and in patients with renal disease and secondary hyperparathyroidism. Enhanced EOF has also been shown in patients with chronic renal failure but did not correlate with PTH levels. We studied a group of patients with primary hyperparathyroidism with and without anaemia, and patients with secondary hyperparathyroidism and anaemia. We found that EOF studies in these patients did not differ from normal control groups and that there was no relation between PTH, EOF, and haematocrit in either study group. We conclude that PTH over a range of concentrations seen in vivo does not affect erythrocyte osmotic fragility or cause anaemia.
甲状旁腺激素（PTH）在体外已被证明可增强红细胞渗透脆性（EOF），并且被认为是原发性甲状旁腺功能亢进患者以及肾病和继发性甲状旁腺功能亢进患者所出现贫血的一个因素。慢性肾衰竭患者也出现了EOF增强的情况，但这与PTH水平无关。我们研究了一组患有或未患贫血的原发性甲状旁腺功能亢进患者，以及患有继发性甲状旁腺功能亢进和贫血的患者。我们发现，这些患者的EOF研究结果与正常对照组并无差异，且在任何一个研究组中，PTH、EOF和血细胞比容之间均无关联。我们得出结论，在体内所见的一系列浓度范围内，PTH不会影响红细胞渗透脆性或导致贫血。
